MX2007001663A - Formulacion de interferon pegilado estable. - Google Patents

Formulacion de interferon pegilado estable.

Info

Publication number: MX2007001663A
Authority: MX; Mexico
Prior art keywords: further characterized; solution; interferon; pegylated interferon; trehalose
Prior art date: 2004-08-12

Application number

MX2007001663A

Other languages

English (en)

Spanish (es)

Inventor

Mohammed Shameem

Anita Dabbara

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-12

Filing date

2005-08-11

Publication date

2007-04-10

2005-08-11 Application filed by Schering Corp filed Critical Schering Corp

2007-04-10 Publication of MX2007001663A publication Critical patent/MX2007001663A/es

Links

108010050904 Interferons Proteins 0.000 title claims abstract description 102
102000014150 Interferons Human genes 0.000 title claims abstract description 102
229940079322 interferon Drugs 0.000 title claims abstract description 99
239000000203 mixture Substances 0.000 title claims abstract description 71
238000009472 formulation Methods 0.000 title claims abstract description 64
239000002577 cryoprotective agent Substances 0.000 claims abstract description 55
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 41
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 41
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 41
238000000034 method Methods 0.000 claims abstract description 13
238000003860 storage Methods 0.000 claims abstract description 11
239000000243 solution Substances 0.000 claims description 48
229940074410 trehalose Drugs 0.000 claims description 40
239000008176 lyophilized powder Substances 0.000 claims description 31
238000004108 freeze drying Methods 0.000 claims description 27
239000011521 glass Substances 0.000 claims description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
239000003381 stabilizer Substances 0.000 claims description 17
229930006000 Sucrose Natural products 0.000 claims description 15
229940126534 drug product Drugs 0.000 claims description 15
239000000825 pharmaceutical preparation Substances 0.000 claims description 15
239000005720 sucrose Substances 0.000 claims description 15
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
238000001035 drying Methods 0.000 claims description 14
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 12
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
229940068968 polysorbate 80 Drugs 0.000 claims description 12
229920000053 polysorbate 80 Polymers 0.000 claims description 12
239000008215 water for injection Substances 0.000 claims description 10
108010047761 Interferon-alpha Proteins 0.000 claims description 9
102000006992 Interferon-alpha Human genes 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 9
229940075564 anhydrous dibasic sodium phosphate Drugs 0.000 claims description 7
229920000136 polysorbate Polymers 0.000 claims description 6
DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 5
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical class [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 5
BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 5
229940074409 trehalose dihydrate Drugs 0.000 claims description 5
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 4
229960003507 interferon alfa-2b Drugs 0.000 claims description 4
238000000137 annealing Methods 0.000 claims description 3
238000007710 freezing Methods 0.000 claims description 3
230000008014 freezing Effects 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
150000003625 trehaloses Chemical class 0.000 claims description 3
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 2
108010078049 Interferon alpha-2 Proteins 0.000 claims description 2
238000011068 loading method Methods 0.000 claims description 2
239000007853 buffer solution Substances 0.000 claims 6
229950008882 polysorbate Drugs 0.000 claims 4
239000000872 buffer Substances 0.000 claims 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
229910000162 sodium phosphate Inorganic materials 0.000 claims 2
239000001488 sodium phosphate Substances 0.000 claims 2
235000011008 sodium phosphates Nutrition 0.000 claims 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
229910000397 disodium phosphate Inorganic materials 0.000 claims 1
235000019800 disodium phosphate Nutrition 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 claims 1
229920001223 polyethylene glycol Polymers 0.000 description 21
239000002202 Polyethylene glycol Substances 0.000 description 20
229960004793 sucrose Drugs 0.000 description 14
230000007547 defect Effects 0.000 description 10
229940047124 interferons Drugs 0.000 description 9
108010092851 peginterferon alfa-2b Proteins 0.000 description 7
229940106366 pegintron Drugs 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 5
230000008569 process Effects 0.000 description 5
150000001720 carbohydrates Chemical class 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000021615 conjugation Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000008227 sterile water for injection Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
230000008859 change Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
150000002016 disaccharides Chemical class 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000007787 solid Substances 0.000 description 3
-1 Biogen Idee) Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
108010005716 Interferon beta-1a Proteins 0.000 description 2
108010005714 Interferon beta-1b Proteins 0.000 description 2
108090000467 Interferon-beta Proteins 0.000 description 2
102000003996 Interferon-beta Human genes 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000012931 lyophilized formulation Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102100040018 Interferon alpha-2 Human genes 0.000 description 1
108010079944 Interferon-alpha2b Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010061307 Neck deformity Diseases 0.000 description 1
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229940099550 actimmune Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940003504 avonex Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940021459 betaseron Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229940061631 citric acid acetate Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000000959 cryoprotective effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229940090438 infergen Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
108010055511 interferon alfa-2c Proteins 0.000 description 1
108010010648 interferon alfacon-1 Proteins 0.000 description 1
229960004461 interferon beta-1a Drugs 0.000 description 1
229960003161 interferon beta-1b Drugs 0.000 description 1
108010042414 interferon gamma-1b Proteins 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229920001427 mPEG Polymers 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960003931 peginterferon alfa-2b Drugs 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229940075562 sodium phosphate dihydrate Drugs 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
125000000185 sucrose group Chemical group 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

MX2007001663A 2004-08-12 2005-08-11 Formulacion de interferon pegilado estable. MX2007001663A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60084604P	2004-08-12	2004-08-12
PCT/US2005/028441 WO2006020720A2 (en)	2004-08-12	2005-08-11	Stable pegylated interferon formulation

Publications (1)

Publication Number	Publication Date
MX2007001663A true MX2007001663A (es)	2007-04-10

Family

ID=35885766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2007001663A MX2007001663A (es)	2004-08-12	2005-08-11	Formulacion de interferon pegilado estable.

Country Status (15)

Country	Link
US (1)	US7632491B2 (pt)
EP (1)	EP1796647B1 (pt)
JP (1)	JP4971160B2 (pt)
KR (1)	KR20070045244A (pt)
CN (1)	CN101039660B (pt)
AT (1)	ATE476967T1 (pt)
AU (1)	AU2005272862B2 (pt)
BR (1)	BRPI0513332A (pt)
CA (1)	CA2576549C (pt)
DE (1)	DE602005022895D1 (pt)
ES (1)	ES2349472T3 (pt)
MX (1)	MX2007001663A (pt)
NO (1)	NO20071341L (pt)
WO (1)	WO2006020720A2 (pt)
ZA (1)	ZA200701154B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2107069B1 (en)	2003-08-05	2013-01-16	Novo Nordisk A/S	Novel insulin derivatives
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
PL2097068T3 (pl)	2006-11-24	2013-12-31	Cadila Healthcare Ltd	Preparaty koniugatów PEG-interferon alfa
ATE512660T1 (de)	2007-03-05	2011-07-15	Cadila Healthcare Ltd	Zusammensetzungen mit peg-interferon-alpha- konjugaten und raffinose als kryoschutzmittel
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
BRPI0821029A2 (pt) *	2007-12-20	2015-06-16	Merck Serono Sa	Fomulações de peg-interferon-beta
ES2968301T3 (es) *	2008-08-05	2024-05-08	Wyeth Llc	Liofilización por encima del colapso
KR20110085985A (ko)	2008-10-30	2011-07-27	노보 노르디스크 에이/에스	하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
WO2010064258A2 (en) *	2008-12-01	2010-06-10	Intas Biopharmaceuticals Limited	Pharmaceutical formulations of interferon conjugates
BR112013010345A2 (pt)	2010-10-27	2017-07-25	Novo Nordisk As	tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
WO2012118687A1 (en) *	2011-02-28	2012-09-07	Merck Sharp & Dohme Corp.	Manually operated injector with restricted injection sequence
SI2701720T1 (sl)	2011-04-28	2017-11-30	Oncopeptides Ab	Liofilizirani pripravek citotoksičnih dipeptidov
KR20150074167A (ko) *	2012-10-26	2015-07-01	루핀 리미티드	Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물
HK1217633A1 (zh) *	2013-01-15	2017-01-20	Teva Pharmaceutical Industries Ltd.	冻乾方法
CN103054818B (zh) *	2013-01-28	2014-03-05	苏州二叶制药有限公司	一种优质高效的冷冻干燥技术
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
GB201513010D0 (en) *	2015-07-23	2015-09-09	Glaxosmithkline Biolog Sa	Novel formulation
FI126979B (en) *	2016-02-29	2017-09-15	Faron Pharmaceuticals Oy	Lyophilized pharmaceutical formulation and its use
CN108379561B (zh) *	2018-03-01	2021-11-26	修正生物医药（杭州）研究院有限公司	一种聚乙二醇化尿酸氧化酶冻干粉剂及其制备方法
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR102562968B1 (ko) *	2018-11-01	2023-08-04	주식회사 셀비온	붕소 중성자 포획 치료용 파라-보로노페닐알라닌 조성물 및 이의 제조방법
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
CN112245570A (zh) *	2019-07-22	2021-01-22	厦门特宝生物工程股份有限公司	一种基于干扰素的疾病治疗方法
CN112807281A (zh) *	2019-10-31	2021-05-18	南京海维医药科技有限公司	包含血管紧张素ii的稳定组合物及其制备方法、使用方法
CA3194975A1 (en) *	2020-09-11	2022-03-17	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Methods for preparation of a terminally sterilized hydrogel or colloidal suspension derived from extracellular matrix, and uses thereof
CN113797318B (zh) *	2021-10-26	2023-06-30	深圳科兴药业有限公司	一种干扰素组合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3262575D1 (en) *	1981-12-23	1985-04-18	Schering Corp	Stabilised interferon formulations and their preparation
CA2024046A1 (en)	1989-09-28	1991-03-29	Alberto Ferro	Stabilized leukocyte-interferons
US5595732A (en) *	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
US5951974A (en)	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
DE69430251T2 (de)	1993-11-10	2002-11-07	Enzon, Inc.	Verbesserte interferon-polymerkonjugate
US5766582A (en)	1994-10-11	1998-06-16	Schering Corporation	Stable, aqueous alfa interferon solution formulations
US5738846A (en)	1994-11-10	1998-04-14	Enzon, Inc.	Interferon polymer conjugates and process for preparing the same
US5691298A (en) *	1994-12-14	1997-11-25	The Procter & Gamble Company	Ester oligomers suitable as soil release agents in detergent compositions
JP2000510813A (ja)	1995-02-06	2000-08-22	ジェネテイックス・インスティテュート・インコーポレイテッド	Ｉｌ−１２用処方
TW426523B (en)	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
TW517067B (en)	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
JP3643034B2 (ja) *	1998-03-26	2005-04-27	シェーリングコーポレイション	ＰＥＧ−インターフェロンα結合体の保護のための処方物
US6180096B1 (en) *	1998-03-26	2001-01-30	Schering Corporation	Formulations for protection of peg-interferon alpha conjugates
HUP0202525A3 (en) *	1999-08-13	2003-11-28	Hoffmann La Roche	Mycophenolate mofetil in association with peg-ifn-alpha, medicaments and kit comprising thereof
US6887462B2 (en) *	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
AU2002346686A1 (en) *	2001-12-07	2003-06-23	Intermune, Inc.	Compositions and method for treating hepatitis virus infection

2005
- 2005-08-11 DE DE602005022895T patent/DE602005022895D1/de not_active Expired - Lifetime
- 2005-08-11 CN CN2005800348502A patent/CN101039660B/zh not_active Expired - Fee Related
- 2005-08-11 ES ES05785190T patent/ES2349472T3/es not_active Expired - Lifetime
- 2005-08-11 AU AU2005272862A patent/AU2005272862B2/en not_active Ceased
- 2005-08-11 WO PCT/US2005/028441 patent/WO2006020720A2/en not_active Ceased
- 2005-08-11 EP EP05785190A patent/EP1796647B1/en not_active Expired - Lifetime
- 2005-08-11 JP JP2007525768A patent/JP4971160B2/ja not_active Expired - Fee Related
- 2005-08-11 BR BRPI0513332-7A patent/BRPI0513332A/pt not_active IP Right Cessation
- 2005-08-11 MX MX2007001663A patent/MX2007001663A/es active IP Right Grant
- 2005-08-11 CA CA2576549A patent/CA2576549C/en not_active Expired - Fee Related
- 2005-08-11 US US11/201,731 patent/US7632491B2/en active Active
- 2005-08-11 AT AT05785190T patent/ATE476967T1/de not_active IP Right Cessation
- 2005-08-11 KR KR1020077003190A patent/KR20070045244A/ko not_active Withdrawn
2007
- 2007-02-08 ZA ZA200701154A patent/ZA200701154B/xx unknown
- 2007-03-12 NO NO20071341A patent/NO20071341L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HK1103977A1 (en)	2008-01-04
NO20071341L (no)	2007-03-12
WO2006020720A3 (en)	2006-06-01
CN101039660A (zh)	2007-09-19
ATE476967T1 (de)	2010-08-15
AU2005272862A1 (en)	2006-02-23
JP4971160B2 (ja)	2012-07-11
ZA200701154B (en)	2008-08-27
EP1796647A2 (en)	2007-06-20
US7632491B2 (en)	2009-12-15
US20060051320A1 (en)	2006-03-09
KR20070045244A (ko)	2007-05-02
EP1796647B1 (en)	2010-08-11
CA2576549A1 (en)	2006-02-23
BRPI0513332A (pt)	2008-05-06
WO2006020720A2 (en)	2006-02-23
JP2008509919A (ja)	2008-04-03
CA2576549C (en)	2011-01-18
ES2349472T3 (es)	2011-01-03
DE602005022895D1 (de)	2010-09-23
CN101039660B (zh)	2010-10-06
AU2005272862B2 (en)	2011-03-10

Legal Events

Date	Code	Title	Description
2010-03-30	FG	Grant or registration
2010-08-12	HH	Correction or change in general
2012-09-14	HC	Change of company name or juridical status	Owner name: SOLSTICE NEUROSCIENCES, INC.

Publication	Publication Date	Title
AU2005272862B2 (en)	2011-03-10	Stable pegylated interferon formulation
US4496537A (en)	1985-01-29	Biologically stable alpha-interferon formulations
US5981485A (en)	1999-11-09	Human growth hormone aqueous formulation
KR100457485B1 (ko)	2005-02-02	안정한 트란스글루타미나제 제형 및 이의 제조 방법
EP1308170B1 (en)	2008-11-12	Dried blood factor composition comprising trehalose
US6180096B1 (en)	2001-01-30	Formulations for protection of peg-interferon alpha conjugates
JPH07509719A (ja)	1995-10-26	ヒト成長ホルモン水性製剤
TWI243057B (en)	2005-11-11	Formulations for protection of peg-interferon alpha conjugates
CN108379561B (zh)	2021-11-26	一种聚乙二醇化尿酸氧化酶冻干粉剂及其制备方法
US5714458A (en)	1998-02-03	Stable pharmaceutical compositions containing a fibroblast growth factor
JP3100058B2 (ja)	2000-10-16	線維芽細胞成長因子を含む安定な医薬組成物
HU205555B (en)	1992-05-28	Process for producing stabilized leukocyte interferons
JPH0543689B2 (pt)	1993-07-02
HK1103977B (en)	2010-11-05	Stable pegylated interferon formulation
HK1029754B (en)	2005-08-05	Formulations for protection of peg-interferon alpha conjugates
HK1117766A (en)	2009-01-23	Dried blood factor composition stabilised by trehalose